Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for its novel, potential ...

Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

In this video, Lukas Delasos, DO, discusses the accelerated approval of zongertinib as an initial treatment option for adults ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Investors Are Buying Now. Summit Therapeutics climbed by 15.44 ...

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical ...

Findings showed the ORR was 76% (95% CI, 65-85), with 11% achieving complete response and 65% achieving partial response. The Food and Drug Administration has granted accelerated approval to Hernexeos ...